Final Guidance for Medicare Drug Price Negotiation Program

The U.S. Department of HHS and CMS released final guidance on October 2 outlining the process for the second cycle of negotiations under the Medicare Drug Price Negotiation Program. The guidance includes information on how CMS will help ensure people with Medicare can access drugs at the negotiated prices when the prices become effective. CMS will announce the selection of up to 15 additional drugs covered by Part D for the second cycle of negotiations by February 1, 2025. This final guidance includes lessons learned from the first cycle of negotiations and comments received. Additionally, the final guidance outlines improvements to the design of patient-focused engagement events. Read the release to learn more.